1
|
Read M, Henshaw KD, Zaharieva DP, Brown TC, Varga AE, Bray C, Cox M, Goody-Rohdin PJ, Hider K, Jelleyman P, Jenkins A, Jones C, Kerr P, Leach R, Martin K, Oreskovic N, O'Sullivan G, Rucioch J, Sims C, Smart C, Speight J, Stanistreet J, Tippett M, Tivalu I, Withers T, O'Neal DN. "Empowering Us": A Community-Led Survey of Real-World Perspectives of Adults with Type 1 Diabetes Using Insulin Pumps and Continuous Glucose Monitoring to Manage Their Glucose Levels. Diabetes Res Clin Pract 2023:110830. [PMID: 37451626 DOI: 10.1016/j.diabres.2023.110830] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 07/09/2023] [Accepted: 07/12/2023] [Indexed: 07/18/2023]
Abstract
OBJECTIVE To conduct an Australian community-led survey of adults with type 1 diabetes (T1D), identifying priorities for, and barriers to, optimal use of advanced glucose management technologies. RESEARCH DESIGN AND METHODS A 30-question online survey of current or past users of insulin pump therapy (IPT), real-time continuous glucose monitoring (RT-CGM), or intermittently scanned CGM (isCGM) explored perceptions regarding device design, access, education, outcomes, and support. RESULTS Between November 2021 and January 2022, surveys were completed by 3,380 participants (age [mean±SD] 45±16 years; 62% female; 20±14 years diabetes), with 55%, 82%, and 55% reporting experience with IPT, RT-CGM, and isCGM, respectively. Overall, most considered diabetes technology '(extremely) important' for maintaining target glucose levels (98%) and reducing hypoglycaemia severity and frequency (93%). For most, technology contributed positively to emotional well-being (IPT 89%; RT-CGM 91%; isCGM 87%), which was associated with device effectiveness in maintaining glucose in range, comfort, and convenience. Barriers included affordability (IPT 68%; RT-CGM 81%; isCGM 69%) and insufficient information for informed choices about device suitability (IPT 39%; RT-CGM 41%; isCGM 36%). CONCLUSIONS Technology is perceived by adults with T1D as important for managing glycaemia and emotional well-being. Modifiable barriers to use include affordability, and information regarding device suitability.
Collapse
Affiliation(s)
| | | | - Dessi P Zaharieva
- Diabetes Victoria, Carlton, Victoria, Australia; Division of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | - Tim C Brown
- Diabetes Victoria, Carlton, Victoria, Australia; School of Mathematics, Monash University, Clayton, Victoria, Australia
| | | | | | | | | | - Kim Hider
- Diabetes Victoria, Carlton, Victoria, Australia
| | | | - Alicia Jenkins
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia; Department of Endocrinology, St Vincent's Hospital Melbourne, Victoria, Australia; Australian Centre for Accelerating Diabetes Innovations, The University of Melbourne, Parkville, Victoria, Australia; The Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
| | | | - Peggy Kerr
- Diabetes Victoria, Carlton, Victoria, Australia
| | - Rob Leach
- Diabetes Victoria, Carlton, Victoria, Australia
| | - Kim Martin
- Diabetes Victoria, Carlton, Victoria, Australia
| | | | | | | | - Catriona Sims
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
| | - Carmel Smart
- John Hunter Children's Hospital, Newcastle, New South Wales, Australia; School of Health Sciences, University of Newcastle, Newcastle, New South Wales, Australia
| | - Jane Speight
- Deakin University, School of Psychology, Institute of Health Transformation, Geelong, Victoria, Australia; The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Carlton, Victoria, Australia; Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia
| | | | | | | | | | - David N O'Neal
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia; Department of Endocrinology, St Vincent's Hospital Melbourne, Victoria, Australia; Australian Centre for Accelerating Diabetes Innovations, The University of Melbourne, Parkville, Victoria, Australia.
| |
Collapse
|